Bioorganic and Medicinal Chemistry Letters p. 3500 - 3503 (2008)
Update date:2022-07-29
Topics:
McAtee, John J.
Dodson, Jason W.
Dowdell, Sarah E.
Girard, Gerald R.
Goodman, Krista B.
Hilfiker, Mark A.
Sehon, Clark A.
Sha, Deyou
Wang, Gren Z.
Wang, Ning
Viet, Andrew Q.
Zhang, Daohua
Aiyar, Nambi V.
Behm, David J.
Carballo, Luz H.
Evans, Christopher A.
Fries, Harvey E.
Nagilla, Rakesh
Roethke, Theresa J.
Xu, Xiaoping
Yuan, Catherine C.K.
Douglas, Stephen A.
Neeb, Michael J.
This work describes the development of potent and selective human Urotensin-II receptor antagonists starting from lead compound 1, (3,4-dichlorophenyl)methyl{2-oxo-2-[3-phenyl-2-(1-pyrrolidinylmethyl)-1-piperidinyl]ethyl}amine. Several problems relating to oral bioavailability, cytochrome P450 inhibition, and off-target activity at the kappa opioid receptor and cardiac sodium channel were addressed during lead development. hUT binding affinity relative to compound 1 was improved by more than 40-fold in some analogs, and a structural modification was identified which significantly attenuated both off-target activities.
View MoreHebei Kangtai Pharmaceutical Co.,Ltd
Contact:+86-0317-3512963
Address:Wugang Road,Mengcun of Cangzhou City,Hebei Province ,China
Zhengzhou Yuanli Biological Technology Co., Ltd.
Contact:+86-371-67897870/67897895
Address:No. 38, Qingyang Street, Zhengzhou, Henan, China
Taixing Joxin Bio-tec Co.,Ltd.
website:http://www.joxbio.com
Contact:86-523-87558858 87612088
Address:No.88, chengdong industrial park
LinHai Cina Chemical Co., LTD.
Contact:0576-85580989
Address:Pharma-chem zone,Duqiao,Linhai,Zhejiang,China
Lishui Nanming Chemical Co., Ltd(expird)
Contact:+86-0578-2134101,2697830
Address:No.19 Tongji Road Shuige Industrial zone
Doi:10.1039/jr9500000859
(1950)Doi:10.1021/ol802939u
(2009)Doi:10.1002/anie.201004619
(2010)Doi:10.1016/S0040-4039(00)94312-0
(1983)Doi:10.1002/ejoc.201701477
(2018)Doi:10.1021/jo00236a001
(1988)